1,673 material Form 8-K filings that 1,260 companies we cover made with the SEC in February 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Ziff Davis reported preliminary unaudited fourth-quarter 2025 revenue of $406.7 million, down from $412.8 million a year earlier, and net income of $0.4 million versus $64.1 million, including a $58.0 million pre-tax loss on a business sale. Full-year revenue rose 3.5% to $1.45 billion, but the company deferred its fiscal 2026 guidance while it evaluates possible sales of entire divisions, which leaves shareholders without a forecast for next year.
Q4 2025 revenue was $406.7 million, down from $412.8 million in Q4 2024; diluted EPS was $0.01 versus $1.43.
Full-year 2025 revenue rose 3.5% to $1.45 billion; GAAP diluted EPS fell to $1.15 from $1.42, while adjusted diluted EPS rose 0.2% to $6.63.
Fiscal 2026 guidance is deferred while outside advisers evaluate value-creating opportunities, including the potential sale of entire divisions.
The company repurchased $173.8 million of its stock in 2025 and reported free cash flow of $287.9 million; the earnings call is set for February 24, 2026 at 8:30 a.m. ET.
Vir Biotechnology agreed with Astellas on a global collaboration to co-develop and co-commercialize VIR-5500, a Phase 1 prostate cancer candidate, with closing subject to U.S. antitrust clearance. The same day, the company reported 2025 results: full-year revenue fell to $68.6 million while the full-year net loss narrowed to $438.0 million.
Vir to receive $335 million in upfront and near-term milestone payments, including $240 million in cash, a $75 million equity investment and a $20 million milestone
Astellas agreed to buy 7,239,382 shares at $10.36 per share, a 50% premium to the 30-day volume weighted average price as of February 17, 2026
Vir is eligible for up to $1.37 billion in future milestones; U.S. profit and loss are shared equally and Vir holds a U.S. co-promotion option
Full-year 2025 revenue was $68.6 million versus $74.2 million in 2024; full-year net loss was $438.0 million, or $(3.16) per share, versus $522.0 million, or $(3.83) per share
Innovex reported fourth-quarter 2025 revenue of $274 million, up 14% from the prior quarter, but net income fell to $14 million from $39 million in the third quarter and $32 million a year earlier. The company guided first-quarter 2026 revenue to $225 million to $235 million and Adjusted EBITDA to $38 million to $42 million, both below its fourth-quarter results, citing lower subsea deliveries and seasonality.
Q4 2025 revenue of $274 million, up from $240 million in Q3 2025 and $251 million in Q4 2024
Q4 2025 net income of $14 million (5% margin) and diluted EPS of $0.20, versus $0.57 in Q3 2025
Q4 2025 Adjusted EBITDA of $52 million (19% margin); full-year 2025 free cash flow of $156 million
Q1 2026 guidance: revenue of $225 million to $235 million and Adjusted EBITDA of $38 million to $42 million
Novanta reported fourth-quarter and full-year 2025 results on February 23, 2026, with quarterly GAAP revenue up 9% and adjusted diluted EPS up 20%. Full-year GAAP diluted EPS fell to $1.47 from $1.77, and operating cash flow declined sharply, while the company issued 2026 revenue guidance of $1,030 million to $1,050 million.
Q4 2025 GAAP revenue was $258.3 million, up 9%, while GAAP diluted EPS was $0.45 versus $0.46 a year earlier.
Q4 2025 adjusted diluted EPS was $0.91, up 20%; operating cash flow was $8.8 million versus $61.6 million.
Full-year 2025 GAAP revenue was $980.6 million, up 3.3%, and GAAP diluted EPS was $1.47 versus $1.77.
2026 guidance: GAAP revenue of $1,030 million to $1,050 million and adjusted diluted EPS of $3.50 to $3.65.
Primoris Services reported fourth-quarter and full-year 2025 results on February 23, 2026. Full-year revenue and net income rose, but fourth-quarter net income fell 4.1% on higher costs on certain renewables projects and lower storm restoration work. The company expects 2026 GAAP earnings of $5.35 to $5.55 per diluted share and declared a $0.08 quarterly dividend.
Full-year 2025 revenue was $7.6 billion, up 19.0%, and net income was $274.9 million, or $5.02 per diluted share, up 52.0%.
Fourth-quarter 2025 net income was $51.8 million, or $0.95 per diluted share, down 4.1%, while revenue was $1.9 billion, up 6.7%.
2026 outlook: EPS of $5.35 to $5.55 per diluted share; adjusted EPS of $5.80 to $6.00.
Board declared a $0.08 per share cash dividend, with a record date of March 31, 2026, payable on or about April 15, 2026.
Atlas Energy Solutions reported fourth-quarter and full-year 2025 results, with revenue up 3.7% to $1.1 billion but a net loss of $50.3 million, compared with net income of $59.9 million in 2024. Adjusted EBITDA fell to $221.7 million from $288.9 million, and the company expects first-quarter 2026 EBITDA to be flat with the fourth quarter, which shareholders will weigh against the full-year swing to a loss.
Full-year 2025 revenue was $1.1 billion, up $39.4 million, or 3.7%, from 2024; net loss was $(50.3) million versus net income of $59.9 million in 2024.
Fourth-quarter 2025 revenue was $249.4 million, down 3.9% from the third quarter, with a net loss of $(22.2) million and Adjusted EBITDA of $36.7 million.
Q1 2026 guidance: EBITDA expected to be flat with fourth-quarter results, reflecting lower realized sand pricing and about $6 million of weather impact in January.
Company is targeting approximately 500 MW of power generation capacity deployed in 2027; total liquidity was $108.5 million as of December 31, 2025.
Quaker Chemical reported fourth-quarter 2025 net sales of $468.5 million, up 6%, and net income of $20.7 million, or $1.18 per diluted share, versus $0.81 a year earlier. For the full year, the company posted a net loss of $2.5 million, or $0.14 per share, compared with net income of $116.6 million in 2024, after an $88.8 million impairment charge and $35.1 million of restructuring charges. Management expects end markets to remain at similar levels through the first half of 2026 and says it is confident in revenue and adjusted EBITDA growth in 2026, but the filing gives no numeric guidance.
Q4 2025 net sales were $468.5 million, up from $444.1 million; net income was $20.7 million, or $1.18 per diluted share, versus $0.81 a year earlier.
Full-year 2025 net loss of $2.5 million ($0.14 per diluted share) compared with net income of $116.6 million in 2024, including an $88.8 million impairment charge.
Q4 adjusted EBITDA rose 11% to $71.9 million; full-year non-GAAP EPS was $7.02 versus $7.44.
Operating cash flow was $136.5 million in 2025 versus $204.6 million in 2024; net debt was $691.4 million at December 31, 2025.
HealthStream reported record fourth-quarter 2025 revenue of $79.7 million, up 7.4%, but GAAP net income fell 48.1% to $2.5 million, mainly due to a $3.8 million charge tied to its CEO's stock contribution. The company also gave 2026 guidance of $323.0 million to $330.0 million in revenue and declared a quarterly dividend of $0.035 per share, up 12.9%.
Q4 2025 revenue $79.7 million, up 7.4% from $74.2 million; GAAP operating income $2.4 million, down 48.8%
$3.8 million charge from the CEO Stock Gift; GAAP diluted EPS $0.09 vs. $0.16 a year earlier, and non-GAAP diluted EPS $0.18
2026 guidance: revenue $323.0 million to $330.0 million; net income $20.4 million to $22.8 million
Quarterly dividend of $0.035 per share, up from $0.031, payable March 20, 2026 to holders of record on March 9, 2026
JBT Marel reported fourth quarter and full year 2025 results, with full year revenue of $3.8 billion and a loss from continuing operations of $50 million, compared with income of $84.6 million in 2024. The company also issued 2026 guidance calling for revenue of $3,990 million to $4,065 million and adjusted EPS of $8.00 to $8.50, which matters to shareholders because the 2025 GAAP loss was driven by a $147 million pension settlement charge and $115 million in M&A costs, while adjusted EPS rose to $6.41 from $6.15.
Full year 2025 revenue was $3.8 billion, up from $1.7 billion in 2024, and fourth quarter revenue was $1,008.0 million versus $467.6 million a year earlier.
Full year 2025 diluted loss per share from continuing operations was $0.96, compared with diluted earnings of $2.63 in 2024; adjusted EPS was $6.41 versus $6.15.
Full year 2026 guidance: revenue of $3,990 million to $4,065 million, GAAP EPS of $4.70 to $5.15, and adjusted EBITDA of $675 million to $710 million.
Full year 2025 free cash flow was $250 million, and net debt to trailing twelve months adjusted EBITDA was 2.9x; an Investor Day is scheduled for March 26, 2026.
Clearway Energy reported full-year 2025 revenue of $1,429 million, up from $1,371 million, and Adjusted EBITDA of $1,217 million, up from $1,146 million. Its consolidated net loss widened to $231 million from $63 million, although net income attributable to the company rose to $169 million, or $1.43 per share, from $88 million, or $0.75 per share. The company reaffirmed its 2026 CAFD guidance of $470 million to $510 million.
Full-year 2025 revenue was $1,429 million versus $1,371 million in 2024; Adjusted EBITDA was $1,217 million versus $1,146 million.
Net loss was $231 million versus $63 million in 2024, while net income attributable to Clearway Energy was $169 million, or $1.43 per share, versus $88 million, or $0.75 per share.
Cash Available for Distribution (CAFD) was $430 million versus $425 million in 2024; 2026 CAFD guidance of $470 million to $510 million was reaffirmed.
Total liquidity was $1,061 million at December 31, 2025, down $269 million from 2024; the company closed $600 million of 2034 senior notes in January 2026.
Erie Indemnity reported fourth-quarter 2025 net income of $63.4 million, or $1.21 per diluted share, down from $152.0 million, or $2.91, a year earlier. Full-year 2025 net income was $559.3 million, or $10.69 per diluted share, versus $600.3 million, or $11.48, in 2024. Total operating revenue rose in both periods, but the company's $100 million charitable contribution to the Erie Insurance Foundation reduced net income by $80.6 million after tax, or $1.54 per diluted share.
Q4 2025 net income $63.4 million, or $1.21 per diluted share, versus $152.0 million, or $2.91, in Q4 2024
Full-year 2025 net income $559.3 million, or $10.69 per diluted share, versus $600.3 million, or $11.48, in 2024
Total operating revenue $951.0 million in Q4 2025 versus $924.1 million in Q4 2024
Board approved dividend No. 383 of $1.4625 per Class A share, payable April 21, 2026 to holders of record April 7, 2026
Adeia reported record fourth-quarter 2025 revenue of $182.6 million, up from $119.2 million a year earlier, and full-year 2025 revenue of $443.4 million, up from $376.0 million. Its 2026 outlook calls for revenue of $395.0 million to $435.0 million and GAAP net income of $57.2 million to $80.4 million, both below the 2025 actual results of $443.4 million and $111.1 million.
Q4 2025 GAAP diluted EPS was $0.65, versus $0.32 in Q4 2024; non-GAAP diluted EPS was $0.86.
Full-year 2025 GAAP net income was $111.1 million and adjusted EBITDA was $277.6 million.
2026 guidance: revenue $395.0 million to $435.0 million; GAAP net income $57.2 million to $80.4 million; adjusted EBITDA $213.4 million to $245.4 million.
A long-term license agreement with Disney was signed in Q4 2025, resolving all outstanding litigation.
BioMarin reported fourth-quarter 2025 revenue of $875 million, up 17% from a year earlier, but swung to a GAAP net loss of $47 million after about $240 million in charges tied to its decision to withdraw ROCTAVIAN from the market. The company guided 2026 total revenue to $3.325 billion to $3.425 billion and non-GAAP diluted EPS to $4.95 to $5.15, excluding the pending Amicus Therapeutics acquisition, which is expected to close in the second quarter of 2026.
Q4 2025 total revenue was $875 million, up 17%; VOXZOGO revenue rose 31% to $273 million.
Q4 2025 GAAP net loss was $47 million, or $(0.24) per diluted share, compared with net income of $125 million in Q4 2024.
2026 guidance: total revenue of $3.325 billion to $3.425 billion and non-GAAP diluted EPS of $4.95 to $5.15, versus $3.15 for 2025.
Full-year 2025 GAAP diluted EPS was $1.80, down from $2.21 in 2024; guidance excludes any contribution from Amicus, expected to close in Q2 2026.
Hims & Hers reported fourth-quarter and full-year 2025 results, with revenue up 59% for the year to $2.35 billion and full-year net income of $128.4 million. Fourth-quarter net income fell from $26.0 million a year earlier, and gross margin dropped to 72% from 77%. The company guided to 2026 revenue of $2.7 billion to $2.9 billion and Adjusted EBITDA of $300 million to $375 million, excluding the proposed Eucalyptus acquisition.
Q4 2025 revenue was $617.8 million, up 28% from $481.1 million; full-year revenue was $2.35 billion, up 59%.
Q4 2025 net income was $20.6 million versus $26.0 million in Q4 2024; full-year net income was $128.4 million versus $126.0 million.
Full-year 2025 Adjusted EBITDA was $318.0 million versus $176.9 million in 2024; Q4 free cash flow was $(2.6) million versus $59.5 million.
2026 guidance: first-quarter revenue of $600 million to $625 million and full-year revenue of $2.7 billion to $2.9 billion; guidance excludes the proposed Eucalyptus acquisition, expected to close mid-2026.
Diamondback Energy reported a fourth-quarter 2025 net loss attributable to the company of $1,458 million, driven by a $3,652 million impairment of oil and natural gas properties, compared with net income of $1,074 million a year earlier. The company raised its annual base dividend 5% to $4.20 per share and gave 2026 guidance of 500 to 510 MBO/d of oil production and $3.6 billion to $3.9 billion of total capital expenditures. The dividend increase benefits shareholders, while the reported loss and impairment weigh on reported results.
Q4 2025 net loss attributable to Diamondback of $1,458 million, or $5.11 per diluted share, versus net income of $1,074 million, or $3.67 per share, in Q4 2024.
Impairment of oil and natural gas properties of $3,652 million in Q4 2025, compared with none in Q4 2024.
Adjusted net income of $499 million, or $1.74 per diluted share, for Q4 2025.
Annual base dividend increased 5% to $4.20 per share; Q4 2025 base dividend of $1.05 per share is payable March 12, 2026.
Viper Energy reported a fourth-quarter 2025 net loss attributable to Viper of $103 million, or $0.61 per Class A share, compared with net income of $210 million a year earlier. Total operating income rose to $435 million from $229 million, but a $408 million non-cash impairment drove the loss. The company also raised its annual base dividend 15% to $1.52 per share and increased its share repurchase authorization by $1.0 billion.
Q4 2025 total operating income was $435 million, up from $229 million in Q4 2024; net loss attributable to Viper was $103 million, versus $210 million of net income a year earlier.
The $408 million impairment relates to properties acquired from Diamondback in the May 1, 2025 drop down transaction, recorded at Diamondback's historical carrying value.
Base dividend increases 15% to $1.52 per share annually, starting with the Q4 2025 dividend; Q4 2025 base dividend is $0.38 and variable dividend is $0.14 per share, payable March 12, 2026.
Share repurchase authorization increased by $1.0 billion; approximately $1.2 billion remains under the program.
Stepan Company approved Project Catalyst, a plan targeting about $100 million in pre-tax savings over two years. The plan closes its Fieldsboro, New Jersey site and decommissions select assets at Elwood, Illinois and Stalybridge, United Kingdom, with completion expected by mid-2026. The company expects $70 to $80 million in restructuring charges in 2026, which will weigh on near-term results against the projected savings.
Target of approximately $100 million in pre-tax savings over the next two years
Restructuring charges of $70 to $80 million expected in 2026, with about $52 to $62 million in the three months ending March 31, 2026
Projected cash impacts of $29 to $44 million and non-cash impacts of $58 to $62 million over the project
Fieldsboro site closure and asset decommissioning expected to be completed by mid-2026
Stepan reported fourth-quarter and full-year 2025 results and announced Project Catalyst, a plan it says is expected to deliver about $100 million in pre-tax savings over two years, including closing its Fieldsboro, NJ site. Full-year 2025 net income fell 7% to $46.9 million and adjusted earnings per diluted share fell 17% to $1.82, while net sales rose 7% to $2.33 billion. The company also declared a $0.395 quarterly dividend payable March 13, 2026.
Q4 2025 net income was $5.0 million, up 49%; adjusted net income was a $0.5 million loss versus $2.8 million of income a year earlier
Full-year 2025 adjusted EBITDA was $198.9 million, up 6%; net sales were $2.33 billion, up 7%
Project Catalyst is expected to deliver about $100 million in pre-tax savings over two years and includes closing the Fieldsboro, NJ site
Quarterly dividend of $0.395 per share is payable March 13, 2026, to holders of record on March 2, 2026
Easterly Government Properties reported fourth-quarter 2025 revenue of $87.0 million, up from $78.3 million a year earlier, but net income fell to $4.8 million ($0.10 per share) from $5.7 million ($0.13 per share). The company maintained its 2026 Core FFO per share guidance of $3.05 to $3.12 and declared a $0.45 per share dividend for the fourth quarter, payable March 19, 2026.
Q4 2025 revenue $87.0 million vs. $78.3 million in Q4 2024; net income $4.8 million, $0.10 per share, vs. $5.7 million, $0.13 per share
Q4 2025 Core FFO $36.8 million, or $0.77 per share on a fully diluted basis; full-year 2025 Core FFO $140.1 million, or $2.99 per share
2026 full-year Core FFO per share guidance maintained at $3.05 to $3.12
Quarterly cash dividend of $0.45 per common share, payable March 19, 2026, to holders of record on March 5, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.